Search

Your search keyword '"Mcdaniel, K"' showing total 273 results
Start Over Author "Mcdaniel, K"
273 results on '"Mcdaniel, K"'

1. Case report: Persistent Müllerian duct syndrome and enlarged prostatic utricle in a male dog

Author

Welsh, PJ, McDaniel, K, Goldsmith, EW, Ramsay, JD, Conley, A, Owen, TJ, Ambrosini, YM, and Ciccarelli, M

Subjects
Veterinary Sciences, Veterinary sciences
Abstract

A 1-year-old male intact Miniature Schnauzer mix was presented for chronic intermittent hematuria. Abdominal ultrasonography revealed a large, fluid-filled cystic structure extending cranially and dorsally to the prostate. Computed tomography scan images revealed that the fluid-filled cavity resembled a uterus, with both horns entering the scrotum through the inguinal canal adjacent to the testes. On cytogenetic analysis, the dog was found to have a homozygote mutation on AMHRII consistent with persistent Müllerian duct syndrome (PMDS). A gonadohysterectomy was performed, and surgical and histologic findings confirmed the presence of a uterus, oviducts, vagina, and testes in this dog. Additionally, an intraoperative fluoroscopy exam revealed a communication between the uterus and the bladder via an enlarged utricle, explaining the hematuria and urine in the reproductive tract (urometra). To our knowledge, this is the first clinical report of a phenotypically intact male dog with PMDS and urometra due to an enlarged prostatic utricle. This case illustrates a combination of a disorder of sex and urogenital sinus development.

Published
2023

3. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

Author

Matza LS, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, Braun A, Van Brunt K, and McDaniel K

Subjects
Medicine (General), R5-920
Abstract

Louis S Matza,1 Ze Cong,2 Karen Chung,2 Alison Stopeck,3 Katia Tonkin,4 Janet Brown,5 Ada Braun,2 Kate Van Brunt,6 Kelly McDaniel1 1Outcomes Research, United BioSource Corporation, Bethesda, MD, USA; 2Amgen, Inc, Thousand Oaks, CA, USA; 3Department of Medicine, University of Arizona, Tucson, AZ, USA; 4Department of Oncology, University of Alberta, Edmonton, Alberta, Canada; 5Leeds Institute of Molecular Medicine, St James University Hospital, Leeds, UK; 6formerly with Outcomes Research, United BioSource Corporation, Bethesda, MD, USA Introduction: Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for bone metastases is frequently administered via intravenous infusion, while a newer treatment is administered as a subcutaneous injection. This study estimated the impact of these treatment modalities on health state preference. Methods: Participants from the UK general population completed time trade-off interviews to assess the utility of health state vignettes. Respondents first rated a health state representing cancer with bone metastases. Subsequent health states added descriptions of treatment modalities (ie, injection or infusion) to this basic health state. The two treatment modalities were presented with and without chemotherapy, and infusion characteristics were varied by duration (30 minutes or 2 hours) and renal monitoring. Results: A total of 121 participants completed the interviews (52.1% female, 76.9% white). Cancer with bone metastases had a mean utility of 0.40 on a standard utility scale (1 = full health; 0 = dead). The injection, 30-minute infusion, and 2-hour infusion had mean disutilities of −0.004, −0.02, and −0.04, respectively. The mean disutility of the 30-minute infusion was greater with renal monitoring than without. Chemotherapy was associated with substantial disutility (−0.17). When added to health states with chemotherapy, the mean disutilities of injection, 30-minute infusion, and 2-hour infusion were −0.02, −0.03, and −0.04, respectively. The disutility associated with injection was significantly lower than the disutility of the 30-minute and 2-hour infusions (P < 0.05), regardless of chemotherapy status. Conclusion: Respondents perceived an inconvenience with each type of treatment modality, but injections were preferred over infusions. The resulting utilities may be used in cost-utility models examining the value of treatments for the prevention of skeletal-related events in patients with bone metastases. Keywords: skeletal-related event, infusion, injection

Published
2013

5. Comorbidity Risk Factors Contributing to COVID-19 Related Deaths in Florida, March 1, 2020-January 16, 2021

Author

Weiss Uk, McDaniel K, Marie A. Bailey, Rivkees Sa, Cohen A, and Maynard Jd

Subjects
medicine.medical_specialty, Heart disease, business.industry, Odds ratio, Disease, medicine.disease, Chronic liver disease, Comorbidity, Internal medicine, Medicine, Dementia, business, Kidney disease, Cause of death
Abstract

ObjectivesTo assess the association of specific comorbid conditions to COVID-19 deaths in Florida among decedents 16 to 64 years of age.MethodsThis report uses Florida vital statistics death data over the period of March 1, 2020 through January 16, 2021, to estimate the effects of comorbid conditions on COVID-19 mortality for decedents 16 to 64 years of age. All cases of COVID-19 death occurring in Florida, regardless of resident status, were evaluated. The comorbidities, or contributing causes of death, identified in this report include Down syndrome, asthma, diabetes, pulmonary fibrosis, obesity, dementia, immunodeficiency, kidney disease, chronic obstructive pulmonary disease, hypertension, heart disease, and chronic liver disease and cirrhosis. The study uses a binary logistic regression to examine the relationship between COVID-19 and non-COVID-19 death and contributing causes of death based on information in the death record. Odds ratios were calculated as a residual of the logistic regression.ResultsAmong COVID-19 deaths, Down syndrome was 15.26 times more likely to be a contributing cause of death compared to non-COVID-19 deaths followed by asthma (OR 7.74), diabetes (OR 6.11), pulmonary fibrosis (OR 5.13), obesity (OR 4.66), dementia (OR 4.51), immunodeficiency (OR 2.49), and kidney disease (OR 2.13). Chronic liver disease and cirrhosis (OR 0.95) and cancer (OR 0.79) had lower odds of being a contributing cause of death.ConclusionsHeart disease, chronic liver disease and cirrhosis, and cancer were not risk factors for death from COVID-19 among decedents. Additional studies are needed to elucidate associations between race/ethnicity, socioeconomic status, and behavioral factors.

Published
2021
Full Text
View/download PDF

8. Effect of clinical signs, endocrinopathies, timing of surgery, hyperlipidemia, and hyperbilirubinemia on outcome in dogs with gallbladder mucocele

Author

Jaffey, J. A., Pavlick, M., Webster, C. R., Moore, G. E., McDaniel, K. A., Blois, S. L., Brand, E. M., Reich, C. F., Motschenbacher, L., Hostnik, E. T., Su, D., Lidbury, J. A., Raab, O., Carr, S. V., Mabry, K. E., Fox-Alvarez, W., Townsend, S., Palermo, S., Nakazono, Y., Ohno, K., VanEerde, E., Fieten, H., Hulsman, A. H., Cooley-Lock, K., Dunning, M., Kisielewicz, C., Zoia, A., Caldin, M., Conti-Patara, A., Ross, L., Mansfield, C., Lynn, O., Claus, M. A., Watson, P. J., Swallow, A., Yool, D. A., Gommeren, K., Knops, M., Ceplecha, V., de Rooster, H., Lobetti, R., Dossin, O., Jolivet, F., Papazoglou, L. G., Pappalardo, M. C.F., Manczur, F., Dudás-Györki, Z., O'Neill, E. J., Martinez, C., Gal, A., Owen, R. L., Gunn, E., Brown, K., Harder, L. K., Griebsch, C., Anfinsen, K. P., Gron, T. K., Marchetti, V., Heilmann, R. M., Pazzi, P., DeClue, A. E., dCSCA RMSC-1, dCSCA AVR, LS Interne geneeskunde, University of Missouri [Columbia] (Mizzou), University of Missouri System, Tufts University, Purdue University, University of Guelph, Michigan State University [East Lansing], Michigan State University System, University of Minnesota [Twin Cities] (UMN), University of Minnesota System, Ohio State University, Partenaires INRAE, University of Tennessee, Texas A&M University System, University of Prince Edward Island, Virginia Tech [Blacksburg], University of Florida [Gainesville] (UF), University of Pennsylvania, The University of Tokyo (UTokyo), Iowa State University (ISU), Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University [Utrecht], Department of Clinical Sciences, College of Veterinary Medicine, Cornell University [New York], University of Nottingham, UK (UON), San Marco Veterinary Clinic, Washington State University (WSU), University of Melbourne, Murdoch University, Department of Veterinary Medicine, University of Cambridge [UK] (CAM), University of Edinburgh, Université de Liège, University of Veterinary and Pharmaceutical Sciences [Brno] (VFU), Universiteit Gent = Ghent University [Belgium] (UGENT), Bryanston Veterinary Hospital, Institut de Recherche en Santé Digestive (IRSD ), Institut National de la Recherche Agronomique (INRA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Aristotle University of Thessaloniki, Department of Support, Production and Animal Health, School of Veterinary Medicine, University of Veterinary Medicine, University of Dublin, Massey University, University of Glasgow, University of Veterinary Medicine Hannover, Department of Animal Nutrition, University of Sydney, Department of Companion Animal Clinical Sciences, Norwegian School of Veterinary Science, University of Pisa, Leipzig University, University of Pretoria [South Africa], Pride Veterinary Centre, dCSCA RMSC-1, dCSCA AVR, LS Interne geneeskunde, Watson, Penelope [0000-0002-7241-9412], and Apollo - University of Cambridge Repository

Subjects
Canine Cushing's, Adrenocortical Hyperfunction, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, Survival, Mucocele, Gallbladder mucocoele, Gastroenterology, 0403 veterinary science, 0302 clinical medicine, gallbladder mucocele, dog, endocrinopathies, Dog Diseases, Subclinical infection, Hyperbilirubinemia, Mortality rate, 04 agricultural and veterinary sciences, Jaundice, 3. Good health, Treatment Outcome, dog, 030211 gastroenterology & hepatology, medicine.symptom, Prognostic variable, medicine.medical_specialty, 040301 veterinary sciences, Gallbladder disease, Hyperlipidemias, Gallbladder Diseases, Canine Cushing’s, 03 medical and health sciences, Dogs, Hypothyroidism, Internal medicine, Diabetes mellitus, medicine, Animals, Genetic Predisposition to Disease, Cholecystectomy, Retrospective Studies, [SDV.BA.MVSA]Life Sciences [q-bio]/Animal biology/Veterinary medicine and animal Health, General Veterinary, business.industry, Retrospective cohort study, Bilirubin, medicine.disease, veterinary(all), endocrinopathies, Animal Science and Zoology, gallbladder mucocele, business, Biomarkers
Abstract

International audience; Gallbladder mucocele (GBM) is a common extra-hepatic biliary syndrome in dogs with death rates ranging from 7 to 45%. Therefore, the aim of this study was to identify the association of survival with variables that could be utilized to improve clinical decisions. A total of 1194 dogs with a gross and histopathological diagnosis of GBM were included from 41 veterinary referral hospitals in this retrospective study. Dogs with GBM that demonstrated abnormal clinical signs had significantly greater odds of death than subclinical dogs in a univariable analysis (OR, 4.2; 95% CI, 2.14–8.23; P < 0.001). The multivariable model indicated that categorical variables including owner recognition of jaundice (OR, 2.12; 95% CI, 1.19–3.77; P = 0.011), concurrent hyperadrenocorticism (OR 1.94; 95% CI, 1.08–3.47; P = 0.026), and Pomeranian breed (OR, 2.46; 95% CI 1.10–5.50; P = 0.029) were associated with increased odds of death, and vomiting was associated with decreased odds of death (OR, 0.48; 95% CI, 0.30–0.72; P = 0.001). Continuous variables in the multivariable model, total serum/plasma bilirubin concentration (OR, 1.03; 95% CI, 1.01– 1.04; P < 0.001) and age (OR, 1.17; 95% CI, 1.08–1.26; P < 0.001), were associated with increased odds of death. The clinical utility of total serum/plasma bilirubin concentration as a biomarker to predict death was poor with a sensitivity of 0.61 (95% CI, 0.54–0.69) and a specificity of 0.63 (95% CI, 0.59–0.66). This study identified several prognostic variables in dogs with GBM including total serum/plasma bilirubin concentration, age, clinical signs, concurrent hyperadrenocorticism, and the Pomeranian breed. The presence of hypothyroidism or diabetes mellitus did not impact outcome in this study.

Published
2019
Full Text
View/download PDF

11. Effect of clinical signs, endocrinopathies, timing of surgery, hyperlipidemia, and hyperbilirubinemia on outcome in dogs with gallbladder mucocele

Author

dCSCA RMSC-1, dCSCA AVR, LS Interne geneeskunde, Jaffey, J. A., Pavlick, M., Webster, C. R., Moore, G. E., McDaniel, K. A., Blois, S. L., Brand, E. M., Reich, C. F., Motschenbacher, L., Hostnik, E. T., Su, D., Lidbury, J. A., Raab, O., Carr, S. V., Mabry, K. E., Fox-Alvarez, W., Townsend, S., Palermo, S., Nakazono, Y., Ohno, K., VanEerde, E., Fieten, H., Hulsman, A. H., Cooley-Lock, K., Dunning, M., Kisielewicz, C., Zoia, A., Caldin, M., Conti-Patara, A., Ross, L., Mansfield, C., Lynn, O., Claus, M. A., Watson, P. J., Swallow, A., Yool, D. A., Gommeren, K., Knops, M., Ceplecha, V., de Rooster, H., Lobetti, R., Dossin, O., Jolivet, F., Papazoglou, L. G., Pappalardo, M. C.F., Manczur, F., Dudás-Györki, Z., O'Neill, E. J., Martinez, C., Gal, A., Owen, R. L., Gunn, E., Brown, K., Harder, L. K., Griebsch, C., Anfinsen, K. P., Gron, T. K., Marchetti, V., Heilmann, R. M., Pazzi, P., DeClue, A. E., dCSCA RMSC-1, dCSCA AVR, LS Interne geneeskunde, Jaffey, J. A., Pavlick, M., Webster, C. R., Moore, G. E., McDaniel, K. A., Blois, S. L., Brand, E. M., Reich, C. F., Motschenbacher, L., Hostnik, E. T., Su, D., Lidbury, J. A., Raab, O., Carr, S. V., Mabry, K. E., Fox-Alvarez, W., Townsend, S., Palermo, S., Nakazono, Y., Ohno, K., VanEerde, E., Fieten, H., Hulsman, A. H., Cooley-Lock, K., Dunning, M., Kisielewicz, C., Zoia, A., Caldin, M., Conti-Patara, A., Ross, L., Mansfield, C., Lynn, O., Claus, M. A., Watson, P. J., Swallow, A., Yool, D. A., Gommeren, K., Knops, M., Ceplecha, V., de Rooster, H., Lobetti, R., Dossin, O., Jolivet, F., Papazoglou, L. G., Pappalardo, M. C.F., Manczur, F., Dudás-Györki, Z., O'Neill, E. J., Martinez, C., Gal, A., Owen, R. L., Gunn, E., Brown, K., Harder, L. K., Griebsch, C., Anfinsen, K. P., Gron, T. K., Marchetti, V., Heilmann, R. M., Pazzi, P., and DeClue, A. E.

Published
2019

14. Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b

Author

Kyritsi, K, Meng, F, Zhou, T, Wu, N, Venter, J, Francis, H, Kennedy, L, Onori, P, Franchitto, A, Bernuzzi, F, Invernizzi, P, Mcdaniel, K, Mancinelli, R, Alvaro, D, Gaudio, E, Alpini, G, Glaser, S, Glaser, S., BERNUZZI, FRANCESCA VERONICA, INVERNIZZI, PIETRO, Kyritsi, K, Meng, F, Zhou, T, Wu, N, Venter, J, Francis, H, Kennedy, L, Onori, P, Franchitto, A, Bernuzzi, F, Invernizzi, P, Mcdaniel, K, Mancinelli, R, Alvaro, D, Gaudio, E, Alpini, G, Glaser, S, Glaser, S., BERNUZZI, FRANCESCA VERONICA, and INVERNIZZI, PIETRO

Abstract

Hepatic fibrosis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterized by accumulation of extracellular matrix proteins. Proliferating cholangiocytes and activated hepatic stellate cells (HSCs) participate in the promotion of liver fibrosis during cholestasis. Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone synthesized by hypothalamic neurons and the biliary epithelium and exerts its biological effects on cholangiocytes by interaction with the receptor subtype (GnRHR1) expressed by cholangiocytes and HSCs. Previously, we demonstrated that administration of GnRH to normal rats increased intrahepatic biliary mass (IBDM) and hepatic fibrosis. Also, miR-200b is associated with the progression of hepatic fibrosis; however, the role of the GnRH/GnRHR1/miR-200b axis in the development of hepatic fibrosis in PSC is unknown. Herein, using the mouse model of PSC (multidrug resistance gene 2 knockout), the hepatic knockdown of GnRH decreased IBDM and liver fibrosis. In vivo and in vitro administration of GnRH increased the expression of miR-200b and fibrosis markers. The GnRH/GnRHR1 axis and miR-200b were up-regulated in human PSC samples. Cetrorelix, a GnRHR1 antagonist, inhibited the expression of fibrotic genes in vitro and decreased IBDM and hepatic fibrosis in vivo. Inhibition of miR-200b decreased the expression of fibrosis genes in vitro in cholangiocyte and HSC lines. Targeting the GnRH/GnRHR1/miR-200b axis may be key for the management of hepatic fibrosis during the progression of PSC.

Published
2017

15. Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡

Author

Mcdaniel, K, Meng, F, Wu, N, Sato, K, Venter, J, Bernuzzi, F, Invernizzi, P, Zhou, T, Kyritsi, K, Wan, Y, Huang, Q, Onori, P, Francis, H, Gaudio, E, Glaser, S, Alpini, G, BERNUZZI, FRANCESCA VERONICA, INVERNIZZI, PIETRO, Alpini, G., Mcdaniel, K, Meng, F, Wu, N, Sato, K, Venter, J, Bernuzzi, F, Invernizzi, P, Zhou, T, Kyritsi, K, Wan, Y, Huang, Q, Onori, P, Francis, H, Gaudio, E, Glaser, S, Alpini, G, BERNUZZI, FRANCESCA VERONICA, INVERNIZZI, PIETRO, and Alpini, G.

Abstract

Biliary-committed progenitor cells (small mouse cholangiocytes; SMCCs) from small bile ducts are more resistant to hepatobiliary injury than large mouse cholangiocytes (LGCCs) from large bile ducts. The definitive endoderm marker, forkhead box A2 (FoxA2), is the key transcriptional factor that regulates cell differentiation and tissue regeneration. Our aim was to characterize the translational role of FoxA2 during cholestatic liver injury. Messenger RNA expression in SMCCs and LGCCs was assessed by polymerase chain reaction (PCR) array analysis. Liver tissues and hepatic stellate cells (HSCs) from primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) patients were tested by real-time PCR for methylation, senescence, and fibrosis markers. Bile duct ligation (BDL) and multidrug resistance protein 2 (MDR2) knockout mice (MDR2-/-) were used as animal models of cholestatic liver injury with or without healthy transplanted large or small cholangiocytes. We demonstrated that FoxA2 was notably enhanced in murine liver progenitor cells and SMCCs and was silenced in human PSC and PBC liver tissues relative to respective controls that are correlated with the epigenetic methylation enzymes, DNA methyltransferase (DNMT) 1 and DNMT3B. Serum alanine aminotransferase and aspartate aminotransferase levels in nonobese diabetic/severe combined immunodeficiency mice engrafted with SMCCs post-BDL showed significant changes compared to vehicle-treated mice, along with improved liver fibrosis. Enhanced expression of FoxA2 was observed in BDL mouse liver after SMCC cell therapy. Furthermore, activation of fibrosis signaling pathways were observed in BDL/MDR2-/- mouse liver as well as in isolated HSCs by laser capture microdissection, and these signals were recovered along with reduced hepatic senescence and enhanced hepatic stellate cellular senescence after SMCC engraft. Conclusion: The definitive endoderm marker and the positive regulator of biliary development, FoxA

Published
2017

16. Gonadotropin-releasing hormone (GnRH) contributes to liver fibrosis in primary sclerosing cholangitis (PSC) through enhanced epithelial-mesenchymal transition (EMT) in small but increased senescence in large cholangiocytes

Author

Kyritsi, T, Wu, N, Invernizzi, P, Venter, J, Zhou, Th, Sato, K, Bernuzzi, F, Mcdaniel, K, Onori, Paolo, Franchitto, Antonio, Gaudio, Eugenio, Francis, Hl, Glaser, Ss, Meng, F, and Alpini, G.

Subjects
liver, biliary tree, gonadotropin-releasing hormone
Published
2016

17. Inhibition of the substance P/neurokinin-1 receptor (NK-1R) axis decreases liver fibrosis in the Mdr2(-/-) mouse model of primary sclerosing cholangitis (PSC) through changes in senescence in cholangiocytes and hepatic stellate cells

Author

Wan, Y, Zhou, Th, Wu, N, Invernizzi, P, Standeford, Ha, Mcdaniel, K, Bernuzzi, F, Venter, J, Onori, Paolo, Gaudio, Eugenio, Franchitto, Antonio, Sato, K, Francis, Hl, Meng, Fy, Alpini, G, and Glaser, Ss

Subjects
PSC, substance P, biliary tree, liver
Published
2016

29. Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and MicroRNA let7a in mice

Author

Glaser, S, Meng, F, Han, Y, Onori, P, Chow, B, Francis, H, Venter, J, Mcdaniel, K, Marzioni, M, Invernizzi, P, Ueno, Y, Lai, J, Huang, L, Standeford, H, Alvaro, D, Gaudio, E, Franchitto, A, Alpini, G, Alpini, G., INVERNIZZI, PIETRO, Glaser, S, Meng, F, Han, Y, Onori, P, Chow, B, Francis, H, Venter, J, Mcdaniel, K, Marzioni, M, Invernizzi, P, Ueno, Y, Lai, J, Huang, L, Standeford, H, Alvaro, D, Gaudio, E, Franchitto, A, Alpini, G, Alpini, G., and INVERNIZZI, PIETRO

Abstract

Background & Aims Proliferating cholangiocytes secrete and respond to neuroendocrine hormones, including secretin. We investigated whether secretin secreted by S cells and cholangiocytes stimulates biliary proliferation in mice. Methods Cholestasis was induced in secretin knockout (Sct-/-) and wild-type (control) mice by bile duct ligation (BDL). At days 3 and 7 after BDL, control and Sct-/- mice received tail-vein injections of morpholinos against microRNA 125b or let7a. One week later, liver tissues and cholangiocytes were collected. Immunohistochemical, immunoblot, luciferase reporter, and real-time polymerase chain reaction assays were performed. Intrahepatic bile duct mass (IBDM) and proliferation were measured. Secretin secretion was measured in conditioned media from cholangiocytes and S cells and in serum and bile. Results Secretin secretion was increased in supernatants from cholangiocytes and S cells and in serum and bile after BDL in control mice. BDL Sct-/- mice had lower IBDM, reduced proliferation, and reduced production of vascular endothelial growth factor (VEGF) A and nerve growth factor (NGF) compared with BDL control. BDL and control mice given morpholinos against microRNA 125b or let7a had increased IBDM. Livers of mice given morpholinos against microRNA 125b had increased expression of VEGFA, and those treated with morpholinos against microRNA let7a had increased expression of NGF. Secretin regulated VEGF and NGF expression that negatively correlated with microRNA 125b and let7a levels in liver tissue. Conclusions After liver injury, secretin produced by cholangiocytes and S cells reduces microRNA 125b and let7a levels, resulting in up-regulation of VEGF and NGF. Modulation of cholangiocyte expression of secretin could be a therapeutic approach for biliary diseases. © 2014 by the AGA Institute.

Published
2014

32. The IPCS collaborative study on neurobehavioral screening methods: IV. control data

Author

Moser, V. C., Becking, G. C., Cuomo, V., Frantik, E., Kulig, B. M., Macphail, R. C., Tilson, H. A., Winneke, G., Brightwell, W. S., Maria Antonietta De Salvia, Gill, M. W., Haggerty, G. C., Hornychova, M., Lammers, J., Larsen, J. -J, Mcdaniel, K. L., Nelson, B. K., Ostergaard, G., and Instituut CIVO-Toxicologie en Voeding TNO TNO Voeding

Subjects
Toxicology
Published
1997

33. The IPCS collaborative study on neurobehavioral screening methods: V. results of chemical testing

Author

Moser, V. C., Becking, G. C., Cuomo, V., Frantik, E., Kulig, B. M., Macphail, R. C., Tilson, H. A., Winneke, G., Brightwell, W. S., Maria Antonietta De Salvia, Gill, M. W., Haggerty, G. C., Hornychova, M., Lammers, J., Larsen, J. -J, Mcdaniel, K. L., Nelson, B. K., Ostergaard, G., and Instituut CIVO-Toxicologie en Voeding TNO TNO Voeding

Subjects
Toxicology
Published
1997

34. In Town Hotels v. Marriott International, court decides for owner on antitrust, unfair competition issues

Author

McDaniel, K. C.

Subjects
Restraint of trade -- Cases, Hotels and motels -- United States, Hotels and motels -- Cases, Antitrust law -- Cases, Company legal issue, Antitrust issue, Banking, finance and accounting industries, Business, Real estate industry, Town Hotels Limited Partnership v. Marriott International, Inc. and Avendra LLC.
Abstract

The federal district court in Charleston, West Virginia, has given its verdict in favor of Town Hotels' owner and against Marriott International and Avendra LLC. Marriott International and Avendra LLC are sued on grounds of antitrust and unfair trading laws.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results